AML3D prints metal submarine parts for the United States Navy. In FY2026 it produced record revenue and its first EBITDA-positive half, and its shares fell about 46 per cent. In September 2026 it turned a copper-nickel qualification programme into its first production parts order, and did not repeat the non-safety-critical qualifier it had used on every earlier one.

Why is the ASX down today? The ASX 200 fell 1.79% by mid-afternoon as rising US bond yields and RBA risk warnings unravelled Wednesday's rally.

Part 3 tests Brightstar's disclosure record against what it delivered, looks at the board and its incentives, sets the company against its peers, sets out the risks specific to it, and closes with Samso's concluding comments.

Rimfire Pacific Mining (ASX RIM) adds column and tank leach tests to its Murga scandium study. Updates and results are due in October and November 2026.

Part 2 reads the 5.17 million ounce Mineral Resource and the 351,000 ounce Ore Reserve, the 2026 drilling at Sandstone, the Laverton mill build and the balance sheet behind a June 2027 quarter target for first gold.

Wiluna Mining (ASX: WMC) seeks A$180 million to relist on the ASX. Samso reviews the Wiluna gold mine, its ASX history, the offer, the funding and the risks.

Samso News unpacks the Identifai Genetics IPO (ASX: ID1), which seeks A$10 million at 20 cents to take its non-invasive prenatal test into a US study.

Brightstar Resources is building a 1.5 million tonne a year gold plant at Laverton, funded to first gold by a US$120 million bond and A$193 million of equity. Part 1 covers how the company was assembled, the three hubs, and what the updated feasibility study actually says.

Stavely Minerals looks like it is recovering. It is higher than six months ago and above its 200-day moving average. This Chart Read tests that impression against the trend measures, then goes through the twelve biggest one-day moves of the year. Seven had no ASX announcement behind them, the biggest was reversed the next day, and one 18.7 per cent rise took A$1,236 of turnover.

EchoIQ sells software that helps cardiologists read heart scans. One of its two products is cleared by the US FDA and is in use in United States hospitals. The other was told on 8 September 2026 that it had not been cleared, and the shares halved the next day.